Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 3092-3102

  De Wolf, Cornelia ^a   Jansen, Robert ^b   Yamaguchi, Hiroaki ^a,d   De Haas, Marcel ^a   Van De Wetering, Koen ^a   Wijnholds, Jan ^c   Beijnen, Jos ^b   Borst, Piet ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADEFOVIR DIPIVOXIL; ADENOSINE PHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; CLADRIBINE; CLOFARABINE; DNA; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MERCAPTOPURINE; MERCAPTOPURINE RIBOSIDE; MULTIDRUG RESISTANCE PROTEIN; NUCLEOTIDE; THIOGUANOSINE;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN HEK293; DRUG TRANSPORT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

6-MERCAPTOPURINE; ADENINE NUCLEOTIDES; ADENOSINE MONOPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE; CLADRIBINE; DOGS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; MICE; NEOPLASM PROTEINS; NUCLEOSIDES; RNA, MESSENGER; TRANSFECTION; TRANSPORT VESICLES;

EID: 54049137262     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0427     Document Type: Article

References (50)

1. Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 2007;26:85-110.
2. Podgorska M, Kocbuch K, Pawelczyk T. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 2005;52:749-58.
3. Staub M, Eriksson S. The role of deoxycytidine kinase in DNA synthesis and nucleoside analogactivation. In: Peters GJ, editor. Deoxynucleoside analogs in cancer therapy. Totowa: Humana Press; 2006. p. 29-52.
4. Munch-Petersen B, Piskur J. Deoxynucleoside kinases and their potential role in deoxynucleoside cytotoxicity. In: Peters GJ, editor. Deoxynucleoside analogs in cancer therapy. Totowa: Humana Press; 2006. p. 53-79.
5. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Med 1999;5:1048-51.
6. Chen Z-S, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4: resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276:33747-54.
7. Adachi M, Reid G, Schuetz JD. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev 2002;54:1333-42.
8. Turriziani O, Schuetz JD, Focher F, et al. Impaired 2′,3′- dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrugre sistant protein 4 with a possible role for ATP-bindingcasset te C11. Biochem J 2002;368:325-32.
9. Adachi M, Sampath J, Lan L-B, et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002;277:38998-9004.
10. Wielinga PR, Reid G, Challa EE, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002;62:1321-32.
11. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analogdrug s by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003;63:1103.
12. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III, Dantzig AH. The multidrugr esistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005;4:855-63.
13. Borst P, Wielinga P. Pumping out drugs. The potential impact of ABC transporters on resistance to base, nucleoside, and nucleotide analogs. In: Peters GJ, editor. Deoxynucleoside analogs in cancer therapy. Totowa: Humana Press; 2006. p. 109-17.
14. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007;71:619-27.
15. Wijnholds J, Mol CAAM, Van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleoside analogs. Proc Natl Acad Sci U S A 2000;97:7476-81.
16. Guo Y, Kotova E, Chen Z-S, et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′- phosphonylmethoxyethyl) adenine. J Biol Chem 2003;278:29509-14.
17. Wang X, Furukawa T, Nitanda T, et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 2003;63:65-72.
18. Wang X, Nitanda T, Shi M, et al. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 2004;68:1363-70.
19. Takenaka K, Morgan JA, Scheffer GL, et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 2007;67:6965-72.
20. Van Herwaarden AE, Schinkel AH. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 2006;27:10-6.
21. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006;86:1179-236.
22. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determiningits relevance in clinical drugresistance. Cancer Metastasis Rev 2007;26:39-57.
23. 2) into milk. Mol Cell Biol 2007;27:1247-53.
24. Jedlitschky G, Burchell B, Keppler D. The multidrugresist ance protein 5 (MRP5) functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000;275:30069-74.
25. Van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002;13:595-603.
26. Wielinga PR, Van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003;278:17664-71.
27. Jedlitschky G, Tirschmann K, Lubenow LE, et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 2004;104:3603-10.
28. De Wolf CJ, Yamaguchi H, Van der Heijden I, et al. cGMP transport by vesicles from human and mouse erythrocytes. FEBS J 2007;274:439-50.
29. Kovács T, Ötvös L. Simple synthesis of 5-vinyl- and 5-ethynyl-2″-deoxyuridine-5′-triphosphates. Tetrahedron Letters 1988;29:4525-8.
30. Fischer B, Boyer JL, Hoyle CH, et al. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5′-triphosphate. J Med Chem 1993;36:3937-46.
31. Jansen RS, Rosing H, De Wolf CJ, Beijnen JH. Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium usingweak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:4049-59.
32. Pavek P, Merino G, Wag enaar E, et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 2005;312:144-52.
33. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-6.
34. Michiels F, Van der Kammen RA, Janssen L, Nolan G, Collard JG. Expression of Rho GTPases usingretroviral vectors. Methods Enzymol 2000;325:295-302.
35. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 2002;99:15649-54.
36. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening . J Natl Cancer Inst 1990;82:1107-12.
37. Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64:5804-11.
38. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drugtransp ort by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001;276:46400-7.
39. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance1. Cancer Res 1998;58:5337-9.
40. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/ Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59:4237-41.
41. Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003;22:7524-36.
42. King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006;69:346-53.
43. Allen JD, Van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrugtransporte r in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-25.
44. Draper MP, Martell RL, Levy SB. Indomethacin-mediated reversal of multidrugre sistance and druge fflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 1997;75:810-5.
45. Breedveld P, Pluim D, Cipriani G, et al. The effect of low pH on BCRP (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan and resveratrol in in vitro drugtran sport models. Mol Pharmacol 2007;71:240-9.
46. Chen ZS, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D- glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54.
47. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003;63:5538-43.
48. Pan G, Giri N, Elmquist WF. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 2007;35:1165-73.
49. Van Den Neste E, Cardoen S, Offner F, Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine [review]. Int J Oncol 2005;27:1113-24.
50. Gandhi V, Plunkett W. Clofarabine; Mechanisms of action, pharmacology, and clinical investigations. In: Peters GJ, editor. Deoxynucleoside analogs in cancer therapy. Totowa: Humana Press; 2006. p. 153-71.